ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,914,354 | +141.5% | 250,052 | +212.4% | 3.00% | +167.2% |
| Q2 2023 | $3,691,198 | -65.1% | 80,052 | -69.7% | 1.12% | -61.9% |
| Q1 2023 | $10,580,564 | +31.3% | 264,052 | +51.7% | 2.95% | +18.6% |
| Q4 2022 | $8,060,348 | +12.0% | 174,052 | 0.0% | 2.49% | +7.8% |
| Q3 2022 | $7,197,000 | -95.5% | 174,052 | +1711.2% | 2.31% | +37.4% |
| Q2 2022 | $161,100,000 | +7671.3% | 9,610 | -95.9% | 1.68% | +259.0% |
| Q1 2022 | $2,073,000 | -82.1% | 233,100 | +68.8% | 0.47% | -81.9% |
| Q4 2021 | $11,613,000 | +25.1% | 138,100 | +33.9% | 2.59% | +15.5% |
| Q3 2021 | $9,286,000 | +62.0% | 103,100 | +71.5% | 2.24% | +48.1% |
| Q2 2021 | $5,731,000 | +150.8% | 60,100 | +199.0% | 1.51% | +150.5% |
| Q1 2021 | $2,285,000 | +9.3% | 20,100 | -51.0% | 0.60% | -25.9% |
| Q1 2018 | $2,090,000 | – | 41,000 | – | 0.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 497,899 | $31,617,000 | 3.20% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 390,453 | $24,794,000 | 1.81% |
| First Light Asset Management, LLC | 180,017 | $11,431,000 | 1.59% |
| Rock Springs Capital Management LP | 580,000 | $36,830,000 | 1.33% |
| Capital Impact Advisors, LLC | 36,165 | $2,244,000 | 0.82% |
| SECTOR GAMMA AS | 79,653 | $5,058,000 | 0.81% |
| Verity Asset Management, Inc. | 7,193 | $457,000 | 0.51% |
| Opus Point Partners Management, LLC | 5,064 | $322,000 | 0.48% |
| Capital International Sarl | 52,000 | $3,302,000 | 0.46% |
| PACIFIC VIEW ASSET MANAGEMENT, LLC | 6,216 | $394,000 | 0.43% |